Complement-Dependent Cytotoxicity Assay.

A useful feature of therapeutic antibodies is the ability to kill the cells to which they bind. Antibodies are capable of mediating cell killing in a variety of ways. Apoptosis, complement-mediated mechanisms, and antibody-dependent cellular cytotoxicity are all effects that can be assayed to characterize lead antibody candidates. Extensive, multidose characterizations of a series of candidates can be performed in a short amount of time using assays developed for high-throughput flow cytometry systems. Antibodies that contain the Fc portion of the human IgG1 can activate complement-mediated cell death. One way in which they do this is via direct complement killing of tumor cells by the membrane attack complex, a process usually called complement-dependent cytotoxicity.

Assessment of Antibody-Dependent Cellular Cytotoxicity by Flow Cytometry.

A useful feature of therapeutic antibodies is the ability to kill the cells to which they bind. Antibodies are capable of mediating cell killing in a variety of ways. Apoptosis, complement-mediated mechanisms, and antibody-dependent cellular cytotoxicity (ADCC) are all effects that can be assayed to characterize lead antibody candidates. Extensive, multidose characterizations of a series of candidates can be performed in a short amount of time using assays developed for high-throughput flow cytometry systems. Antibodies that contain the Fc portion of the human IgG1 can activate complement-mediated killing. In the ADCC method described here, cytotoxicity is mediated mostly by natural killer (NK) cells. Thus, if an antibody binds to its target on the surface of a tumor cell, Fc receptors on the surface of the NK cells (effector cells) recognize the bound antibody. This leads to the release of cytotoxic granules containing perforin, granzymes, and interferon γ, a cytokine that can stimulate other cells of the immune system such as T cells.

Simple Multiplexed Antibody-Binding Assay.

This simple protocol tests antibody binding to target antigens on the surface of cells. This assay is powerful because negative controls are built into each well of the screening plates. It can be used to screen crude supernatants from hybridomas, as well as bacterial periplasmic extracts when screening phage libraries. Using cell-permeant dyes allows the negative and positive cell lines to be color-coded and screened in the same well. A variant enzyme-linked immunosorbent assay can be performed where the target antigen is presented on beads.

Assessment of Apoptosis (Programmed Cell Death) by Flow Cytometry.

A useful feature of therapeutic antibodies is the ability to kill the cells to which they bind. Antibodies are capable of mediating cell killing in a variety of ways. Apoptosis, complement-mediated mechanisms, and antibody-dependent cellular cytotoxicity are all effects that can be assayed to characterize lead antibody candidates. Extensive, multidose characterizations of a series of candidates can be performed in a short amount of time using assays developed for high-throughput flow cytometry systems. Here, we describe a simple multiplexed flow assay performed using Annexin V and propidium iodide that measures an early marker of apoptosis. When cells enter apoptosis, phosphatidyl serine (PS), which is normally found on the inside of the cytoplasmic membrane, is found on the extracellular surface of the membrane, thus revealing Annexin V-binding sites. Because binding of Annexin V to PS is calcium dependent, the buffers used for this assay must contain 1 mm calcium. The calcium dependence can also be used to test whether the Annexin V staining is specific. Thus, if the staining is performed in the presence of 1 mm EDTA, binding of Annexin V should be inhibited. The addition of propidium iodide allows subsequent stages of apoptosis and eventual cell death to be distinguished. For flow cytometry, this assay is best performed on suspension cells.

Antibody Screening Using High-Throughput Flow Cytometry.

Because molecular targets addressable with antibody therapeutics are present on the surface of cells or in circulation, they are ideal for screening by cell- or bead-based assays using flow cytometry, a powerful, high-content analysis technique for cells, beads, and other particles in suspension. The ability to analyze thousands of cells per second, combined with multiplexing capabilities, has made this technology indispensable for laboratories performing antibody development work. Advances in this field, particularly in the areas of plate-based sampling and high-throughput flow cytometry, are enabling the use of this technology earlier in the antibody development and discovery process.

Profiling of toxicity and identification of distinct apoptosis profiles using a 384-well high-throughput flow cytometry screening platform.

Methods and techniques used to detect apoptosis have benefited from advances in technologies such as flow cytometry. With a large arsenal of lasers, fluorescent labels, and readily accessible biological targets, it is possible to detect multiple targets with unique combinations of fluorescent spectral signatures from a single sample. Traditional flow cytometry has been limited as a screening tool as the sample throughput has been low, whereas the data analysis and generation of screening relevant results have been complex. The HTFC Screening System running ForeCyt software is an instrument platform designed to perform high-throughput, multiplexed screening with seamless transformation of flow cytometry data into screening hits. We report the results of a screen that simultaneously quantified caspase 3/7 activation, annexin V binding, cell viability, and mitochondrial integrity. Assay performance over 5 days demonstrated robustness, reliability, and performance of the assay. This system is high throughput in that a 384-well plate can be read and fully analyzed within 30 min and is sensitive with an assay window of at least 10-fold for all parameters and a Z' factor of ≥0.75 for all endpoints and time points. From a screen of 231 compounds, 11 representative toxicity profiles highlighting differential activation of apoptotic pathways were identified.

Cell-based screening using high-throughput flow cytometry.

This review describes the use of high-throughput flow cytometry for performing multiplexed cell-based and bead-based screens. With the many advances in cell-based analysis and screening, flow cytometry has historically been underutilized as a screening tool largely due to the limitations in handling large numbers of samples. However, there has been a resurgence in the use of flow cytometry due to a combination of innovations around instrumentation and a growing need for cell-based and bead-based applications. The HTFC™ Screening System (IntelliCyt Corporation, Albuquerque, NM) is a novel flow cytometry-based screening platform that incorporates a fast sample-loading technology, HyperCyt®, with a two-laser, six-parameter flow cytometer and powerful data analysis capabilities. The system is capable of running multiplexed screening assays at speeds of up to 40 wells per minute, enabling the processing of a 96- and 384-well plates in as little as 3 and 12 min, respectively. Embedded in the system is HyperView®, a data analysis software package that allows rapid identification of hits from multiplexed high-throughput flow cytometry screening campaigns. In addition, the software is incorporated into a server-based data management platform that enables seamless data accessibility and collaboration across multiple sites. High-throughput flow cytometry using the HyperCyt technology has been applied to numerous assay areas and screening campaigns, including efflux transporters, whole cell and receptor binding assays, functional G-protein-coupled receptor screening, in vitro toxicology, and antibody screening.